iCAD, Inc. (ICAD) SecondLook Digital Mammography CAD Software Selected for New Italian Feasibility Study

Today, iCAD announced it has provided SecondLook Digital, its digital mammography computer-aided detection (CAD) software, for “Using computer-assisted diagnosis (CAD – Computer Aided Detection) in the current practice of mammography screening programs,” an Italian feasibility study.

The study will compare the accuracy and cost-effectiveness of conventional double reading to single reading with CAD for mammography screenings. In all, 45,000 patients will be enrolled at six sites throughout Italy.

The study will facilitate the gathering of needed information for systematically changing the way mammography screenings are performed in Italy. Double read scans have become outdated and cumbersome in contrast with more advanced screening technologies that are available today. Pioneering technologies like SecondLook Digital allow improved breast cancer detection, earlier treatment, and improved outcomes for patients.

The SecondLook system provides a computerized second review of mammograms, and this closer look enables radiologists to recognize subtle changes in breast tissue that can require a more thorough examination to confirm the presence of cancer. SecondLook also provides improved workflow for mammography centers by enabling radiologists to more quickly identify and review areas of concern and to work more efficiently.

More than 25 published studies support the use of CAD in conjunction with digital mammography. With SecondLook Digital as the benchmark technology for this crucial study, iCAD is confident the study’s results will aid in the establishment of single read with CAD as Italy’s nationally accepted method for mammography screening.

iCAD is an industry leader in providing advanced image analysis, workflow solutions, and radiation therapies for early identification and treatment of common cancers. The company offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography as well as advanced image analysis and workflow solutions for magnetic resonance imaging and breast and prostate cancers, and computed tomography for colorectal cancer. The company’s Xoft System provides radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The system has also been cleared for treating non-melanoma skin cancer and endometrial cancer.

For more information, visit www.icadmed.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html